Quinolinate-driven immune changes in glioblastoma
Official title: Quinolinate-induced immune suppression in glioblastoma
Funded at William Beaumont Hospital Research Inst · NIH-11381131 · Data updated 2026-11-12
Aims to understand how a molecule called quinolinate shapes the immune environment in glioblastoma to find new ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | William Beaumont Hospital Research Inst NIH-funded |
| Lab location | 1 site (Royal Oak, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $380,000 |
| NIH project number | 5R01NS129744-04 |
| Project ID | NIH-11381131 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma or related brain tumors may benefit from advances arising from this research.
✕Less likely to help
The study is focused on understanding mechanisms and may not directly translate to immediate treatments for all patients.
What this research studies
This project studies why glioblastoma evades immune attack by looking at how quinolinate affects macrophages in the brain tumor. Researchers will analyze tumor samples and model systems to uncover how QA pushes immune cells toward a tumor-friendly state. The work may identify targets to modify QA metabolism and improve responses to immunotherapy for GBM patients. The findings could guide future therapies aimed at reprogramming the tumor immune environment.
Why it matters
Potential benefit: If successful, the work could lead to new strategies that make GBM more responsive to immune-based treatments and extend patients’ lives.
How similar studies have gone: Prior research suggests metabolic pathways like QA can influence immune cells, with growing interest but ongoing validation in GBM.
Where this research is happening
-
William Beaumont Hospital Research Inst
Royal Oak, United States Active
Researchers
- Principal investigator: Chinnaiyan, Prakash — William Beaumont Hospital Research Inst
- Study coordinator: Chinnaiyan, Prakash
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.